KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Gilead Sciences (GILD) Debt to Equity (2016 - 2025)

Gilead Sciences' Debt to Equity history spans 17 years, with the latest figure at $1.1 for Q4 2025.

  • For Q4 2025, Debt to Equity fell 20.22% year-over-year to $1.1; the TTM value through Dec 2025 reached $1.1, down 20.22%, while the annual FY2025 figure was $1.1, 20.22% down from the prior year.
  • Debt to Equity reached $1.1 in Q4 2025 per GILD's latest filing, down from $1.16 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of $1.59 in Q1 2021 to a low of $1.1 in Q4 2023.
  • Average Debt to Equity over 5 years is $1.28, with a median of $1.27 recorded in 2021.
  • The largest YoY upside for Debt to Equity was 46.41% in 2021 against a maximum downside of 26.46% in 2021.
  • A 5-year view of Debt to Equity shows it stood at $1.27 in 2021, then fell by 6.13% to $1.19 in 2022, then fell by 7.67% to $1.1 in 2023, then increased by 25.81% to $1.38 in 2024, then dropped by 20.22% to $1.1 in 2025.
  • Per Business Quant, the three most recent readings for GILD's Debt to Equity are $1.1 (Q4 2025), $1.16 (Q3 2025), and $1.27 (Q2 2025).